Varlas Valentin Nicolae, Bostan Georgiana, Nasui Bogdana Adriana, Bacalbasa Nicolae, Pop Anca Lucia
Department of Obstetrics and Gynecology, Filantropia Clinical Hospital, 011132 Bucharest, Romania.
Department of Obstetrics and Gynecology, Carol Davila University of Medicine and Pharmacy, 37 Dionisie Lupu St., 020021 Bucharest, Romania.
Healthcare (Basel). 2021 Apr 14;9(4):464. doi: 10.3390/healthcare9040464.
Induction of labor (IOL) is an event that occurs in up to 25% of pregnancies. In Europe, the misoprostol vaginal insert (MVI-Misodel) was approved for labor induction in 2013. Studies on the outcomes and safety of IOL in obese pregnant women are scarce; no data are available on MVI IOL in high-risk pregnancy obese women (HRPO-late-term, hypertension, diabetes). As the obesity rates are growing steadily in pregnant women, we aimed to evaluate the failure rate for induction and the safety of a 200 μg MVI in obese (body mass index (BMI) >30 kg/m) HRPO compared to that for obese non-high-risk pregnancies (non-HRPO). For this purpose, we conducted a cross-sectional study in "Filantropia" Clinical Hospital, Bucharest, Romania, from June 2017-the date of the initiation of the MVI IOL protocol in our clinic-to September 2019. The primary outcomes were the failure rate, measured by cesarean section (CS) ratio, and secondarily, the safety profile of MVI, analyzed by one-way ANOVA. Out of a total of 11,096 registered live births, IOL was performed on 206 obese patients. Of these, 74 obese pregnant women had their labor induced with MVI (HRPO, = 57, and non-HRPO, = 17). The average maternal age was 29.9 ± 4.8 years (19-44 years). Across the groups, the rate of CS was 29.8% ( = 17) in the HRPO group compared to 23.5% ( = 4) in the non-HRPO group ( = non significant). In the vaginally birth subgroups, the median time from drug administration to delivery was shorter in the HRPO group compared to the non-HRPO group (16.9 ± 6.0 h 95% confidence interval (CI) 15.0-18.8 vs. 19.4 ± 9.2 h 95% CI 13.8-25.0, = 0.03). No significant differences were found regarding the maternal outcomes among the studied groups; in terms of perinatal outcomes of safety, 5.4% ( = 4) of the cases of vaginal delivery for HRPO were associated with neonatal intensive care unit (NICU) admissions. The MVI seems to be an efficient labor induction agent in high-risk pregnancy obese women with good maternal outcomes and low perinatologic complications.
引产(IOL)是一种在高达25%的妊娠中发生的事件。在欧洲,米索前列醇阴道栓剂(MVI-Misodel)于2013年被批准用于引产。关于肥胖孕妇引产结局和安全性的研究很少;目前尚无关于高危妊娠肥胖妇女(HRPO-晚期、高血压、糖尿病)使用MVI引产的数据。由于肥胖孕妇的比例在稳步上升,我们旨在评估与肥胖非高危妊娠(非HRPO)相比,200μg MVI在肥胖(体重指数(BMI)>30kg/m)HRPO孕妇中的引产失败率和安全性。为此,我们于2017年6月(我们诊所开始实施MVI引产方案的日期)至2019年9月在罗马尼亚布加勒斯特的“慈善”临床医院进行了一项横断面研究。主要结局是通过剖宫产(CS)率衡量的失败率,其次是通过单因素方差分析分析的MVI的安全性。在总共11096例登记的活产中,对206例肥胖患者进行了引产。其中,74例肥胖孕妇使用MVI引产(HRPO组57例,非HRPO组17例)。产妇平均年龄为29.9±4.8岁(19-44岁)。在各分组中,HRPO组的CS率为29.8%(n=17),而非HRPO组为23.5%(n=4)(P=无显著性差异)。在经阴道分娩亚组中,HRPO组从给药到分娩的中位时间比非HRPO组短(16.9±6.0小时,95%置信区间(CI)15.0-18.8,而19.4±9.2小时,95%CI 13.8-25.0,P=0.03)。在研究组之间未发现产妇结局有显著差异;就围产期安全性结局而言,HRPO组经阴道分娩的病例中有5.4%(n=4)与新生儿重症监护病房(NICU)入院有关。MVI似乎是高危妊娠肥胖妇女引产的一种有效药物,产妇结局良好,围产期并发症低。